148 related articles for article (PubMed ID: 21705450)
1. Induction of HLA-DP4-restricted anti-survivin Th1 and Th2 responses using an artificial antigen-presenting cell.
Tanaka M; Butler MO; Ansén S; Imataki O; Berezovskaya A; Nadler LM; Hirano N
Clin Cancer Res; 2011 Aug; 17(16):5392-401. PubMed ID: 21705450
[TBL] [Abstract][Full Text] [Related]
2. A peptide epitope derived from the cancer testis antigen HOM-MEL-40/SSX2 capable of inducing CD4⁺ and CD8⁺ T-cell as well as B-cell responses.
Neumann F; Kubuschok B; Ertan K; Schormann C; Stevanovic S; Preuss KD; Schmidt W; Pfreundschuh M
Cancer Immunol Immunother; 2011 Sep; 60(9):1333-46. PubMed ID: 21630107
[TBL] [Abstract][Full Text] [Related]
3. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
[TBL] [Abstract][Full Text] [Related]
4. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
Knutson KL; Disis ML
Cancer Immunol Immunother; 2005 Aug; 54(8):721-8. PubMed ID: 16010587
[TBL] [Abstract][Full Text] [Related]
5. Unconventional cytokine profiles and development of T cell memory in long-term survivors after cancer vaccination.
Kyte JA; Trachsel S; Risberg B; thor Straten P; Lislerud K; Gaudernack G
Cancer Immunol Immunother; 2009 Oct; 58(10):1609-26. PubMed ID: 19221745
[TBL] [Abstract][Full Text] [Related]
6. Selective identification of HLA-DP4 binding T cell epitopes encoded by the MAGE-A gene family.
Wang XF; Cohen WM; Castelli FA; Almunia C; Lethé B; Pouvelle-Moratille S; Munier G; Charron D; Ménez A; Zarour HM; van der Bruggen P; Busson M; Maillère B
Cancer Immunol Immunother; 2007 Jun; 56(6):807-18. PubMed ID: 16988823
[TBL] [Abstract][Full Text] [Related]
7. Critical role of the Th1/Tc1 circuit for the generation of tumor-specific CTL during tumor eradication in vivo by Th1-cell therapy.
Chamoto K; Kosaka A; Tsuji T; Matsuzaki J; Sato T; Takeshima T; Iwakabe K; Togashi Y; Koda T; Nishimura T
Cancer Sci; 2003 Oct; 94(10):924-8. PubMed ID: 14556668
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA.
Kreiter S; Konrad T; Sester M; Huber C; Türeci O; Sahin U
Cancer Immunol Immunother; 2007 Oct; 56(10):1577-87. PubMed ID: 17361438
[TBL] [Abstract][Full Text] [Related]
9. Lineage-specific transcription factors in unexpected places.
Munn DH
Eur J Immunol; 2010 Feb; 40(2):315-7. PubMed ID: 20104569
[TBL] [Abstract][Full Text] [Related]
10. The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design.
Besneux M; Greenshields-Watson A; Scurr MJ; MacLachlan BJ; Christian A; Davies MM; Hargest R; Phillips S; Godkin A; Gallimore A
Cancer Immunol Immunother; 2019 Feb; 68(2):247-256. PubMed ID: 30406375
[TBL] [Abstract][Full Text] [Related]
11. Human CD4+ T cell responses to the dog major allergen Can f 1 and its human homologue tear lipocalin resemble each other.
Liukko AL; Kinnunen TT; Rytkönen-Nissinen MA; Kailaanmäki AH; Randell JT; Maillère B; Virtanen TI
PLoS One; 2014; 9(5):e98461. PubMed ID: 24875388
[TBL] [Abstract][Full Text] [Related]
12. Th1-Dominant CD4
Peng P; Lou Y; Wang J; Wang S; Liu P; Xu LX
Front Immunol; 2022; 13():944115. PubMed ID: 35874660
[TBL] [Abstract][Full Text] [Related]
13. Mesenchymal stromal cells protect tissues from Th1 immune responses via IL-11 secretion.
Cho WJ; Pulimamidi VK; Mittal SK; Chauhan SK
FASEB J; 2024 May; 38(10):e23683. PubMed ID: 38758184
[TBL] [Abstract][Full Text] [Related]
14. Overview of a HLA-Ig based "Lego-like system" for T cell monitoring, modulation and expansion.
Oelke M; Schneck JP
Immunol Res; 2010 Jul; 47(1-3):248-56. PubMed ID: 20087680
[TBL] [Abstract][Full Text] [Related]
15. On the mechanism determining the TH1/TH2 phenotype of an immune response, and its pertinence to strategies for the prevention, and treatment, of certain infectious diseases.
Bretscher PA
Scand J Immunol; 2014 Jun; 79(6):361-76. PubMed ID: 24684592
[TBL] [Abstract][Full Text] [Related]
16. Function and dysfunction of CD4(+) T cells in the immune response to melanoma.
Fischer WH; thor Straten P; Terheyden P; Becker JC
Cancer Immunol Immunother; 1999 Oct; 48(7):363-70. PubMed ID: 10501848
[TBL] [Abstract][Full Text] [Related]
17. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity.
Hirano N; Butler MO; Xia Z; Ansén S; von Bergwelt-Baildon MS; Neuberg D; Freeman GJ; Nadler LM
Blood; 2006 Feb; 107(4):1528-36. PubMed ID: 16239433
[TBL] [Abstract][Full Text] [Related]
18. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy.
Dredge K; Marriott JB; Todryk SM; Dalgleish AG
Cancer Immunol Immunother; 2002 Nov; 51(10):521-31. PubMed ID: 12384803
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions.
Amedei A; Niccolai E; Benagiano M; Della Bella C; Cianchi F; Bechi P; Taddei A; Bencini L; Farsi M; Cappello P; Prisco D; Novelli F; D'Elios MM
Cancer Immunol Immunother; 2013 Jul; 62(7):1249-60. PubMed ID: 23640603
[TBL] [Abstract][Full Text] [Related]
20. Deciphering CD4
Kirkpatrick C; Lu YW
Mol Carcinog; 2024 Jul; 63(7):1209-1220. PubMed ID: 38725218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
